CONFERENCE UPDATES: ACC 2026
FFRangio demonstrates non-inferiority to pressure wire based physiologic assessment in intermediate coronary lesions: Results from the ALL-RISE randomized trial
20 May 2026
Related Articles
Two well-known diabetes drugs similarly effective in reducing heart and kidney disease
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose co-transporter 2 inhibitors (SGLT2i ), which are commonly used to treat type 2 diabetes mellitus (T2DM) are similar in their ability to reduce major heart complications, including heart attack, stroke and death from cardiovascular disease. These findings were accepted for presentation at the Endocrine Society’s Annual Meeting 2020 (ENDO 2020).1,2
29 Jun 2020